Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Apr;39(4):732-5.
doi: 10.1345/aph.1E365. Epub 2005 Feb 22.

Glycoprotein IIb/IIIa inhibitors in patients with end-stage renal disease

Eric Villeneuve  1 , Rubina Sunderji
Affiliations
Review

Glycoprotein IIb/IIIa inhibitors in patients with end-stage renal disease

Eric Villeneuve et al. Ann Pharmacother. 2005 Apr.

Abstract

Objective: To determine whether glycoprotein IIb/IIIa inhibitors (GPIs) are effective and safe as adjunctive therapy for percutaneous coronary intervention (PCI) in patients with end-stage renal disease (ESRD).

Data sources: MEDLINE (1966-June 2004), EMBASE (1980-June 2004), and International Pharmaceutical Abstracts (1970-June 2004) were searched, in addition to a manual bibliographic search.

Data synthesis: Even though GPIs have an established role as adjunctive therapy in PCI, little is known about their use in patients with ESRD. We found 3 reports describing experience with abciximab in this population. Based on the limited information from registries and a retrospective chart review, it is difficult to draw definitive conclusions about the utility of GPIs in ESRD. The decision to use abciximab in this population must be made on an individual case basis.

Conclusions: Studies are needed to evaluate the benefit versus risk of GPI therapy in ESRD.

PubMed Disclaimer

MeSH terms

Substances